Evidence map›Paper›PMID 31404927›Full record

ArticleOpen forum infectious diseases2019

Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response.

E M van Wezel, J de Bruijne, K Damman, M Bijmolen, A P van den Berg, E A M Verschuuren, G A Ruigrok, A Riezebos-Brilman, M Knoester

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Hepatitis E in immunocompromised individuals.World journal of hepatology · 2022
    Review
  10. Transfusion-transmitted hepatitis E: What we know so far?World journal of gastroenterology · 2022
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. A Review of the Diagnosis and Management of Hepatitis E.Current treatment options in infectious diseases · 2020
    Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

E M van WezelDepartment of Clinical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, The Netherlands.
J de BruijneDepartment of Gastroenterology, University of Utrecht, Utrecht University Medical Center, The Netherlands.
K DammanDepartment of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands.
M BijmolenDepartment of Gastroenterology, University of Groningen, University Medical Center Groningen, The Netherlands.
A P van den BergPulmonology and Tuberculosis, University of Groningen, University Medical Center Groningen, The Netherlands.
E A M VerschuurenDepartment of Gastroenterology, University of Utrecht, Utrecht University Medical Center, The Netherlands.
G A RuigrokDepartment of Pulmonology, University of Utrecht, Utrecht University Medical Center, The Netherlands.
A Riezebos-BrilmanDepartment of Clinical Microbiology, University of Utrecht, Utrecht University Medical Center, The Netherlands.
M KnoesterDepartment of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands.
Utrecht University · NLUniversity Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ribavirin is effective for treating immunocompromised patients with chronic hepatitis E virus infection. However, ribavirin treatment is not always successful. We describe 3 solid organ transplant recipients treated with sofosbuvir and ribavirin after failing ribavirin monotherapy. Complete elimination of hepatitis E virus could not be achieved.

Indexed as

chronic hepatitis Esofosbuvirsolid organ transplant recipients

Identifiers

PMID31404927
PMCPMC6690733
OpenAlexW2967681833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.